STAT

OCTOBER 29, 2024

Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Shadowed by the successes of other therapies, the field of cancer vaccines was “seemingly dying,” Sullivan said.

Vaccines 351

Vaccines Immunization Immunity Drug Development 351

PharmaVoice

OCTOBER 29, 2024

As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.

147

147

STAT

OCTOBER 29, 2024

As Chinese biopharma companies rise on the international stage, they are increasingly finding VC partners — in the United States. U.S. companies have long signed licensing deals with Chinese drugmakers. But increasingly American venture capitalists are building U.S.-based companies from scratch to test and ultimately seek to commercialize innovative drugs developed in China.

Drug Development 325

Drug Development 325

Outsourcing Pharma

OCTOBER 29, 2024

Riccardo Butta, a leader at Stevanato Group, delves into how cutting-edge digital twin technology, advanced data management, and AI-driven systems are transforming manufacturing efficiency and quality in the pharmaceutical sector.

85

85

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

STAT

OCTOBER 29, 2024

Ultra-processed foods are part of daily life, filling 60% to 70% of the American diet. That umbrella term covers a wide variety of packaged foods, from snacks carrying added sugar, salt, and saturated fat combined with preservatives for shelf life, additives for flavor, colorants for eye appeal, and chemicals like bisphenols in the packages themselves.

Medical Schools 286

Medical Schools Packaging Labelling Hospitals 286

PharmaVoice

OCTOBER 29, 2024

Pharma pros driving drug development and access for patients with high unmet needs.

Drug Development 130

Drug Development 130

pharmaphorum

OCTOBER 29, 2024

An evaluation of digital health technologies for hypertension by the Peterson Health Technology Institute (PHTI) finds some provide a clinical benefit, while others are lacking.On the plus side, the health technology assessment (HTA) body has concluded that tools to help people manage their antihypertensive drug treatment can deliver benefits in reduced blood pressure.

People Management 83

People Management 83

STAT

OCTOBER 29, 2024

Pfizer released earnings Tuesday that handily beat analyst expectations in the company’s first quarterly report since an activist investor took a $1 billion stake in the drug giant and began putting pressure on its board and CEO. Pfizer reported adjusted earnings per share, a key metric watched by analysts at investment banks, of $1.06 per share compared to expectations of $0.60 per share among analysts surveyed by Visible Alpha.

Drug Development 264

Drug Development 264

pharmaphorum

OCTOBER 29, 2024

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership – which has seen a $150 million upfront payment from Novartis alongside a pledge for up to $2.1 billion in milestones – gives the Swiss pharma group rights to Monte Rosa's VAV1-directed molecular glue degrader programme.

67

67

STAT

OCTOBER 29, 2024

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs.  The company said it anticipates full-year operating profit to grow by a percentage in the high teens, up from the previously forecasted mid- to high teens.  Separately, Novartis CEO Vas Narasimhan said it would be a “couple more years” before the company could submit to regulators an experimental drug for a rare bone marrow cance

261

261

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

The Pharmacist

OCTOBER 29, 2024

The barriers and opportunities involved in working collaboratively across different healthcare professions – including how pharmacists can work across the multidisciplinary team – have been explored during a House of Commons event. The event was hosted by Watford MP Matt Turmaine, sponsored by Dr Bharat Shah of Sigma Pharmaceuticals, and chaired by Professor Mahendra Patel, […] The post 'More we could do' to collaborate across professions, House of Commons event hears appeared fi

67

67

STAT

OCTOBER 29, 2024

This story first appeared in The Readout newsletter.  Sign up for The Readout  and receive STAT’s award-winning biotech news delivered straight to your inbox.  Good morning, it’s a busy earnings week this week. Let’s get straight into reports from Pfizer and Novartis this morning.

Drug Pricing 258

Drug Pricing Drug Development 258

pharmaphorum

OCTOBER 29, 2024

Patients in England and Wales with multiple myeloma are celebrating a decision by NICE to relax strict restrictions on eligibility to receive Pfizer's Elrexfio.In June, the cost-effectiveness agency cleared the use of the BCMAxCD3 bispecific antibody with 'optimised guidance' that allowed it to be used for a narrower range of patients than was covered by the approved label for the drug.

Labelling 65

Labelling 65

STAT

OCTOBER 29, 2024

The historic Inflation Reduction Act of 2022 has fundamentally improved the affordability of and access to prescription drugs for millions of people with Medicare. The law laid out aggressive timelines for implementing the Medicare Drug Price Negotiation Program. As the director of Medicare, my team and I worked thoughtfully and diligently to stand up the program — on time and successfully.

Drug Pricing 215

Drug Pricing 215

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

The Pharmacist

OCTOBER 29, 2024

Pharmacies must contact all patients dispensed a specific batch of the beta blocker labetalol that may contain the wrong medication, the Medicines and Healthcare Products Regulatory Agency (MHRA) has instructed. If batch traceability is not possible, all patients dispensed this product in the last six months must be contacted. In a class two medicines recall […] The post Pharmacies must contact labetalol patients following manufacturing mix-up appeared first on The Pharmacist.

64

64

STAT

OCTOBER 29, 2024

Sen. Elizabeth Warren (D-Mass.) is urging the Federal Trade Commission to scrutinize recent deals from McKesson and Cardinal Health to buy oncology practices, saying those transactions pose “clear, anticompetitive risks.” McKesson, Cardinal Health, and Cencora are the three dominant wholesalers that distribute drugs and medical products.

192

192

BioPharma Dive

OCTOBER 29, 2024

Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ivonescimab, which recently beat Merck’s Keytruda in a Phase 3 trial.

64

64

STAT

OCTOBER 29, 2024

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.  Sign up here. Today’s First Opinion on poop transplants taught me a new word:  fulminant. According to Merriam-Webster, the adjective describes something that comes on “suddenly and with great severity.” Scroll all the way down for context.

Vaccines 167

Vaccines 167

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

BioPharma Dive

OCTOBER 29, 2024

Daniel Quirk, an immunology and neuroscience executive at Bristol Myers Squibb, will be Biogen’s next chief medical officer, while Robin Kramer will replace retiring CFO Michael McDonnell.

64

64

STAT

OCTOBER 29, 2024

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show. But it’s unclear whether the new dosing schedule, if approved by regulators, will convince doctors that the treatment is safer for patients. At 24 weeks of a Phase 3b trial, 24% of those taking the standard regimen experienced a side effect called ARIA-E, a kind of brain swelling.

167

167

BioPharma Dive

OCTOBER 29, 2024

The licensing deal with China’s Chimagen Biosciences is the latest example of drugmaker interest in exploring the potential of “T cell engagers” in autoimmune disease.

64

64

STAT

OCTOBER 29, 2024

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. Hello and happy Tuesday, D.C. Diagnosis readers! We are one week from Election Day; I probably don’t need to remind you.

143

143

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Express Pharma

OCTOBER 29, 2024

In line with the Government’s commitment to ensure the availability of drugs at affordable prices, the National Pharmaceutical Pricing Authority (NPPA) has issued an Office Memorandum dated October 28, 2024, directing the concerned manufacturers to reduce the maximum retail price on three anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab. This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from custom duty.

61

61

STAT

OCTOBER 29, 2024

Ultra-processed foods are part of daily life, filling 60% to 70% of the American diet. That umbrella term covers a wide variety of packaged foods, from snacks carrying added sugar, salt, and saturated fat combined with preservatives for shelf life, additives for flavor, colorants for eye appeal, and chemicals like bisphenols in the packages themselves.

Medical Schools 136

Medical Schools Packaging Labelling Hospitals 136

Express Pharma

OCTOBER 29, 2024

Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. However, the market for oral GLP-1RAs is expanding, and Rybelsus’ latest results showed its benefits in reducing the risk in cardiovascular events in a specific patient population.

Diabetes 60

Diabetes 60

Outsourcing Pharma

OCTOBER 29, 2024

Anu Codaty, VP of global marketing and strategy at Aldevron, is blazing trails in biotech, inspired by a family legacy in medicine and driven to create life-changing therapies.

59

59

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

OCTOBER 29, 2024

AbbVie agrees a $1.4bn cash deal to acquire Aliada Therapeutics, adding another anti-amyloid antibody to its Alzheimer's pipeline.

70

70

Pharmafile

OCTOBER 29, 2024

Chiesi Global Rare Diseases have announced the results from their BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug ELFABRIO at twice the approved dose in patients who have been treated with agalsidase alfa or beta. The current approved dose of pegunigalside alfa-iwxj (ELFABRIO) is 1miligramg (mg) per kilogram (kg) administered every two weeks. […] The post Chiesi announces phase 3 results from enzyme-replacement study appeared first on Pharmafile.

59

59

The Pharmacist

OCTOBER 29, 2024

Informal referrals to community pharmacies deprive pharmacies of more than £115 million each year, Community Pharmacy England (CPE) has estimated. This is the amount that would have been paid if existing referral routes had been used appropriately by GPs and NHS 111, rather than patients being signposted informally to their local community pharmacy.

Community Pharmacies 56

Community Pharmacies 56

pharmaphorum

OCTOBER 29, 2024

UK government confirms £1.8bn funding boost to NHS to cut waiting lists, including £1.

84

84

Outsourcing Pharma

OCTOBER 29, 2024

In a move set to transform drug discovery, CRO NovAliX has partnered with Bruker, a leader in scientific instruments, through a strategic investment aimed at enhancing drug development success rates.

Drug Development 53

Drug Development 53